medigraphic.com
Academia Mexicana de Neurología, A.C.

2006, Number 6

<< Back Next >>

Rev Mex Neuroci 2006; 7 (6)

Prolactinoma with bromocriptine treatment. Long-term follow-up

Millán-Guerrero RO, Núñez-Orozco L, Escobar-Izquierdo A, Isais-Millán S, Ramírez-Gutiérrez R

Language: Spanish
References: 21
Page: 581-585
PDF size: 136.61 Kb.


ABSTRACT

Prolactinomas are a common cause of sexual disfunction and reproduction. Women present amenorrhoea, galactorrea or sterility and men impotence, sterility or libido diminution. Dopaminergic agonists are commonest election in medical treatment of this disease, the most well-known is the bromocriptine. In U.S.A, bromocriptine and pergolide have been accepted several years ago, and recently cabergoline was added to the list; anyone of the three dopaminergic agonists standardizes the prolactose levels and the size of the tumor is reduced 70% in six months. The present work describes the behavior during 10 years of a group of patients with adenoma of hipofisis that were dealt with bromocriptine. We conclude that bromocriptine is safe and effective and represents a dopaminergic agonist well tolerated for the treatment in men and women, in whom gestation is not obtained.


REFERENCES

  1. Zhang X, Sun H, Danila DC, Jonson SR, Zhou Y, Swearigen B, et al. Loss of expression of GADD45 (gamma), a growyh inhibitory gene, in human pituitary adenomas, implications for tumorigenesis.

  2. Arafath MB, Nasrallah MP. Pituitary tumors: pathophysiology, clinical manifestations and management. Endocrine-Related Cancer 2001; 8: 287.

  3. Freda PU, Wardlaw SL. Diagnosis and treatment of pituitary tumors. J Clin Endoc & Metabol 1999; 84: 3859-66.

  4. Burman JAS, Guerra LN, Calabrese MT, Basso A. Bromocriptine and the expresión of c-myc and c-fos in human prolactinomas. Neurol Res 2001; 23: 721-3.

  5. Gruszka A, Pawlikowski M, Kunert-Radek J. Anti-tumoral action of octreotide and bromocriptine on the experimental rat prolactinoma: anti-proliferative and pro-apoptotic effects. Neuroendocorinology Letters 2001; 22: 343-8.

  6. Sabuncu T, Arikan E, Tasan E, Hatemi H. Comparation of the effects of carbegoline and bromocriptine on prolactin levels in hiperprolactinemic patients. Internal Medicine 2001; 40: 857-61.

  7. Vallete-Kasic S, Morange-Ramos I, Selim A, Gunz G, Morange S, Enjalbert A, et al. Macroprolactinemia revisited: A study on 106 patients. J Clin Endoc & Metabol 2002; 87: 581-8.

  8. Molitch ME. Disorders of prolactin secretion. Endocrinology & Metabolism, Clinics of North America 2001; 30(3): 585-610.

  9. Thomson JA, Gray CE, Teasdale GM. Releapse of hyperprolactinemia after transsphenoidal surgery for micriprolactinoma: lessons from long-term follow-up. Neurosurgery 2002; 50: 36-9.

  10. Schopohl J, UGT B. Therapy of pituitary diseases. What can be archieved with medication and hormones? MMW Fortschritte der Medizin 2001; 143: 34-9.

  11. Ciric I, Rosemblatt A, Zhao-Clean. Transsphenoidal microsurgery. Neurosurgery 2002; 51: 161-9.

  12. Orrego JJ, Chandler WF, Barkan AL. Pergolide as primary therapy for macroprolactinomas. Pituitary 2000; 3: 251-6.

  13. Rauhut F, Stuschke M, Sack H, Stolke D. Dependence of the risk of encephalopathy on the radiotherapy volume after combined surgery and radiotherapy of invasive pituitary tumours. Neurochirurgic Act 2002 ; 144: 37-4.

  14. Hulley SB, Gove S, Cummings SR. Elección de los individuos que participarán en el estudio: especificación y muestreo. En Hulley SB,Cummings SR (eds.). Diseño de la Investigación Clínica. España: Harcourt Brace; 1997, p. 21-55.

  15. Millán GR, Isaís CM. Headache associated with pituitary adenomas. Headache 1999; 39: 446.

  16. Abe T, Matsumoto K, Kuwazawa J, Toyoda I, Sasaki K. Headache associated with pituitary adenomas. Headache 1998; 38: 782-6.

  17. Kovacevic S, Cerovski B, Bujger Z, Pastar Z, Petrovic J. Neuroophthalmologic diagnosis of the sella turca region. Collegium antropologicum 2001; Suppl. 25: 63-6.

  18. Asano S, Ueki K, Suzuki I, Kirino T. Clinical features and medical treatment of male prolactinomas. Neurochirurgic Act 2001; 143: 465-70.

  19. Nasseri SS, Kasperbauer JL, Strome SE, McCaffrey TV, Atkinson JL, Meyer FB. Endoscopic transnasal pituitary surgery: report on 180 cases. Am J Rhinology 2001; 15: 281-7.

  20. Björn MP, Lópes MBS, Ellegala DB, Alden TD, Law ER Jr. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurgery 2002; 96: 195-208.

  21. Fukikawa M, Okamura K, Sato K, Shiratsuchi M, Yao T, Mizokami T, et al. J Endocrinological Inv 2001; 24.




2020     |     www.medigraphic.com